Jump to main content
Jump to site search

Issue 6, 2013
Previous Article Next Article

Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands

Author affiliations

Abstract

Organometallic ruthenium(II) arene complexes containing the PTA ligand ([Ru(η6-arene)Cl2(PTA)], PTA = 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane, termed RAPTA) show pharmacologically relevant anti-tumour properties in vitro. Two new enantiomeric pairs of RAPTA compounds, containing the chiral arene (R)- or (S)-2-phenyl-N-(1-phenylethylene)acetamide and either dichlorido or oxalato ligands were synthesised and fully characterised. The stability of the complexes towards hydrolysis was assessed and the dichlorido complexes were found to be more stable towards hydrolysis than the prototype complex RAPTA-C, ([Ru(η6-p-cymene)Cl2(PTA)]). The cytotoxicity of the compounds towards human ovarian cancer cells is moderate to good with a degree of selectivity towards the cancer cells over healthy cells. More significantly, for the first time we were able to establish the influence of a bulky, chiral group attached to the arene on the cytotoxicity of this class of compound, with the S-enantiomer being more cytotoxic than the R-enantiomer.

Graphical abstract: Ruthenium(ii) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands

Back to tab navigation

Supplementary files

Publication details

The article was received on 03 Oct 2012, accepted on 09 Nov 2012 and first published on 12 Nov 2012


Article type: Paper
DOI: 10.1039/C2DT32333H
Citation: Dalton Trans., 2013,42, 2008-2014
  •   Request permissions

    Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands

    K. J. Kilpin, S. M. Cammack, C. M. Clavel and P. J. Dyson, Dalton Trans., 2013, 42, 2008
    DOI: 10.1039/C2DT32333H

Search articles by author

Spotlight

Advertisements